Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Olive oil compounds may shield the aging brain from memory decline

NCT ID NCT07741773

Prevention Sponsor: Augusta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial tests whether a daily supplement of extra-virgin olive oil (EVOO) phenolics can improve memory and brain function in people with mild cognitive impairment (MCI), a condition that sometimes progresses to Alzheimer's disease. Over six months, participants will take either the EVOO supplement or a placebo, and researchers will measure changes in cognitive test scores, brain blood flow, and blood biomarkers linked to Alzheimer's. The goal is to see if this natural compound can slow or prevent the decline toward dementia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
extra-virgin olive oil (EVOO) phenolic dietary supplement
What this could lead to
If successful, this could point toward a simple dietary supplement that helps preserve memory and may delay progression from mild cognitive impairment to Alzheimer's disease.
What could go wrong
This is a small, early-stage trial with only 20 participants, so results may not apply broadly. The supplement may not improve cognition or biomarkers, and the 6-month duration may be too short to see meaningful changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * CDR (Clinical Dementia Rating) score of 0.5 OR MoCA (Montreal Cognitive Assessment) score of 18-25. Exclusion Criteria: * History or presence of vascular disease that may affect cognitive function * History or presence of stroke within the past 1 year * Recent transient ischemic attack (TIA) within the past 180 days * History of severe, clinically significant CNS trauma * History of intracranial tumor * History or presence of kidney disease (eGFR \<60 mL/min/1.73m2) * Presence of a pacemaker * Presence of metal in the body * Allergic to the MRI contrast agent "Multihance" * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild cognitive impairment (MCI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild cognitive impairment (MCI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Georgia prevention institute

    Augusta, Georgia, 30912, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.